Taxotere-Enoxaparin-(ENOXA)-Study

Inclusion Criteria: * Signed informed consent * Men and women aged 18 and older * Locally Advanced or Metastatic Non-small Cell Lung Cancer stage IIIB/IV without any previous therapy * Life expectancy at least 12 weeks * EOCG performance \< 1 * Appropriate renal and hepatic function * Appropriate Hematology * No bleeding events within 4 weeks prior to randomization * No indication for prophylactic or therapeutic anticoagulation therapy * Appropriate methods of contraception (both: men and women) for women of childbearing potential negative urine pregnancy test within 7 day prior to randomization * Capability for s.c. injection of Enoxaparin every 24 hrs Exclusion Criteria: * History of cancer other than NSCLC * Known contraindication for Enoxaparin e.g. HIT, * Known contraindication for Docetaxel, Cisplatin, Carboplatin or co-medication * Participation in any other clinical trials within 30 days prior to randomization * Any known medical condition that does not allow therapy according to study protocol * Seizure disorder